الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
Obesity is a serious universal health problem. It is associated with higher risk of insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular disease. High fat diet has been shown to directly modulate insulin signaling and thus contribute to insulin resistance. Insulin resistance, alone or as part of the metabolic syndrome, is becoming an increasingly common problem in modern society. Insulin resistance is a key etiological factor for T2DM, which has reached epidemic proportions. About 85% of patients who have T2DM are also obese.
Summary and conclusion
Metformin is an oral anti-diabetic drug from the biguanide class that has been shown to reduce blood glucose levels, improve insulin resistance by virtue of its hepato selective insulin-sensitizer action. Rimonabant is a cannabinoid 1 receptor blocker that has been shown to induce weight loss, improve dyslipidemia, hyperglycemia and insulin resistance associated with obesity.
The present work aimed mainly to:
- Explore the metabolic effects of obesity and diabetes and their effect on insulin resistance.
- Examine the possible ameliorating effects of metformin alone and in combination with rimonabant on obesity, T2DM, their metabolic effects and insulin resistance.
The effect of obesity and diabetes on male albino rats and their treatment by metformin alone and in combination with rimonabant were studied. To carry out these investigations, the biochemical parameters were measured:
Summary and Conclusion
6-2
1-Serum: glucose, insulin, total cholesterol, triacylglycerol, high density lipoprotein, low density lipoprotein and tumor necrosis factor alpha.
2-Adipose tissue: adiponectin and resistin expression.